Lyra Therapeutics (LYRA) Misses Q1 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Lyra Therapeutics (LYRA) Misses Q1 EPS by 12c

Lyra Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 11, 2021 4:05 PM EDT

- Presented positive full data from LANTERN Phase 2 study of LYR-210 at COSM

- Appointed Robert Kern, MD, as Chief Medical Officer -

- Conference call and webcast today at 4:30 p.m. ET -

WATERTOWN, Mass.--(BUSINESS WIRE)-- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today reported financial results for the quarter ended March 31, 2021 and... More